Akanda Corp. revenue

Akanda Corp.'s revenue was $258,075 in fiscal 2025, down 69.2% on the year before. Since fiscal 2020 ($2,062) it has grown at a compound 162.7% a year.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Akanda Corp.: revenue history, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	2	41	2,620	424	837	258
Growth on the year before	—	+>999%	+>999%	−83.8%	+97.5%	−69.2%
Gross profit	−58	−2	3,270	59	208	−156
Gross margin	—	−3.8%	—	14.0%	24.9%	−60.5%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Akanda Corp.	$258,075	-69.2%	—
Scienture Holdings, Inc.	$821,315	540.6%	-58.5%
60 Degrees Pharmaceuticals, Inc.	$1.1m	73.2%	74.9%
China SXT Pharmaceuticals, Inc.	$1.1m	-34.6%	—
Lipocine Inc.	$1.6m	-62.7%	205.6%
Nutriband Inc.	$1.6m	-37.3%	-10.8%

Compare with peers

Head to head: AKAN vs SCNX AKAN vs SXTP AKAN vs SXTC

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Akanda Corp.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Akanda Corp.